Ms. Cadden joined QLT in September 2010 as Vice President, Regulatory Affairs and was appointed Vice President, Regulatory and Clinical Affairs in February 2011. She was promoted to Senior Vice President, Development in September 2011. |
Ms. Cadden is responsible for the QLT research and development portfolio, including clinical, pharmaceutical, and formulation development, as well as regulatory affairs.
Ms. Cadden came to QLT with almost 25 years experience in global regulatory affairs, clinical research and drug development. She filled progressively responsible positions at Ciba Canada, where she served as Acting Vice President, Research and Development. At Glaxo Wellcome, in addition to having responsibility for regulatory affairs and clinical compliance, she was a member of the International Regulatory Affairs Board overseeing U.S., E.U. and other regional worldwide drug approval strategies.
Ms. Cadden has held executive positions in established and emerging biotechnology companies in the U.S. and Canada, including Lorus Therapeutics, ActivBiotics, and ImmunoGen, where she has had responsibilities for overseeing global clinical development and regulatory strategies, relationships with regulatory authorities, and achieving global Orphan Drug Designations and associated development strategies.
An author/co-author of numerous publications, Ms. Cadden has been Chair of the BioteCanada Government Relations Committee, Chair of the Rx&D Medical R & D section, and has served on numerous government committees and task forces addressing clinical development and regulatory issues. She holds a B.Sc. in Biochemistry and Nutrition from the University of Guelph and a M.Sc. in Pharmacology from the University of Western Ontario. |
